Biotech success, 2002 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech success, 2002

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (57)	4/29/2002 10:36:27 PM
From: Miljenko Zuanic	Read Replies (1) of 117

After ISIP-LLY deal, this one was new affirmation of the antisense-based drugs, at least for cancer therapy. More important: "One of our clear objectives for achieving sales growth in the coming years is the in-licensing of late-stage development compounds with significant commercial potential, and this agreement is a tangible example of that commitment." EU pharmas (starved for new medicine: SKB, Aventis and Novartis) capitulated recently. US pharmas are bit stubborn, but they are dead in water for some time. If Aventis is paying $500M for Genasense (+ ~$500 M to complete trials, my view), than we will see (in not that distant future) deal worth more than IMCL-BMS, imo. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next